See more : Acri Capital Acquisition Corporation (ACAC) Income Statement Analysis – Financial Results
Complete financial analysis of Lipella Pharmaceuticals Inc. (LIPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipella Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Elmer Bancorp, Inc. (ELMA) Income Statement Analysis – Financial Results
- KRISHNA DEFENCE AN (KRISHNADEF-SM.NS) Income Statement Analysis – Financial Results
- Cantabio Pharmaceuticals, Inc. (CTBO) Income Statement Analysis – Financial Results
- PT Dwi Guna Laksana Tbk (DWGL.JK) Income Statement Analysis – Financial Results
- Marin Software Incorporated (MRIN) Income Statement Analysis – Financial Results
Lipella Pharmaceuticals Inc. (LIPO)
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 449.62K | 184.16K | 259.35K | 961.68K | 694.75K |
| Cost of Revenue | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| Gross Profit | -2.59M | -2.36M | -1.20M | -14.28K | 11.86K |
| Gross Profit Ratio | -575.87% | -1,283.43% | -461.71% | -1.48% | 1.71% |
| Research & Development | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| General & Administrative | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Other Expenses | 0.00 | -45.00 | 57.09K | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 2.77M | 2.18M | 1.02M | 748.54K |
| Cost & Expenses | 5.20M | 2.77M | 2.18M | 1.02M | 748.54K |
| Interest Income | 137.84K | 1.68K | 104.00 | 3.17K | 334.00 |
| Interest Expense | 10.85K | 9.61K | 6.83K | 7.97K | 8.39K |
| Depreciation & Amortization | 1.69K | 2.59M | 1.92M | 56.86K | 53.79K |
| EBITDA | -4.61M | -2.59M | 0.00 | -53.69K | 334.00 |
| EBITDA Ratio | -1,024.52% | -1,405.37% | -716.66% | -5.58% | -7.74% |
| Operating Income | -4.75M | -2.59M | -1.92M | -56.86K | -53.79K |
| Operating Income Ratio | -1,055.55% | -1,406.26% | -738.71% | -5.91% | -7.74% |
| Total Other Income/Expenses | 126.99K | -7.98K | 50.36K | -4.79K | -8.06K |
| Income Before Tax | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
| Income Before Tax Ratio | -1,027.31% | -1,410.59% | -719.30% | -6.41% | -8.90% |
| Income Tax Expense | 0.00 | -1.63K | 6.73K | 4.79K | -53.79K |
| Net Income | -4.62M | -2.60M | -1.87M | -66.45K | -61.85K |
| Net Income Ratio | -1,027.31% | -1,409.71% | -721.89% | -6.91% | -8.90% |
| EPS | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| EPS Diluted | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
| Weighted Avg Shares Out (Dil) | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Peer-reviewed article highlights potential treatment for OLP with focus on localized drug delivery PITTSBURGH, Dec. 03, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today...
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
PITTSBURGH, November 21, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first...
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
PITTSBURGH, November 12, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal...
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug...
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect...
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PITTSBURGH, PA, November 1, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at...
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
PITTSBURGH, PA, October 15, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the...
Source: https://incomestatements.info
Category: Stock Reports